AbbVie Says FTC Can't Fight By Own Rules In Pay-For-Delay
The Federal Trade Commission should be barred from using studies about the pharmaceutical industry at an upcoming pay-for-delay trial over AndroGel, unless the agency turns over the documents underlying those studies,...To view the full article, register now.
Already a subscriber? Click here to view full article